Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme

Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme

Background Modern antiviral treatments have high cure rates against the hepatitis C virus however, the high cost associated with branded medicines and diagnostic tests, have resulted in poor access for many low-income patients residing in low-and-middle-income countries. Objective This study aimed t...

Full description

Bibliographic Details
Main Authors: Ali, M. (Author), Ali, S. (Author), Haque, S. (Author), Lougher, E. (Author), Nawaz, M.S (Author), Paudyal, V. (Author), Rasheed, F. (Author), Ur-Rehman, T. (Author)
Format: Article
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2021
Subjects:
Access to drugs
adult
aged
Antiviral Agents
antivirus agent
Article
chronic hepatitis C
cohort analysis
combination drug therapy
controlled study
cost effectiveness analysis
Developing Countries
developing country
diagnostic cost
drug cost
Drug Therapy, Combination
drug use
evaluation study
female
generic drug
Generic medicines
health care access
health care cost
health care utilization
Hepacivirus
hepatitis C
Hepatitis C
Hepatitis C treatment
Hepatitis C virus subtype 3a
Hepatitis C, Chronic
human
Humans
low income country
Lower-middle-income country
major clinical study
male
middle income country
nonhuman
observational study
out of pocket cost
outcome assessment
Pakistan
patient assistance program
Patient assistant programme
patient care
peginterferon
public hospital
ribavirin
Ribavirin
sofosbuvir
Sofosbuvir
sustained virologic response
very elderly
virus load
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items